MedTrace Logo

Perineural Low-dose Dexamethasone Added to Infraclavicular Block Anesthesia

NCT02698995 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-08-20

No results posted yet for this study

Summary

Dexamethasone has an evidence-based indication in postoperative emesis prophylaxy and as a antiinflammatory steroid. Although the perineural administration is off-label, several studies recognised its analgetic action as an adjuvant for peripheral nerves blockade, permitting to reduce the concentration of the local anesthetics and extending the sensory and motor block.Questions remain concerning the mechanism of action, optimal dose, the lack/degree of toxicity and the comparison with intravenous administration.The aim of this prospective randomized controlled study is to investigate the efficacy of analgesia with 4 mg or 2 mg Dexamethasone added to a combination of ropivacaine 0,5% and lidocaine 1% in vertical infraclavicular blockade (VIB) anesthesia for upper limb surgery.

Conditions

  • Postoperative Pain

Interventions

DRUG

Dexamethasone

One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

DRUG

Ropivacaine

One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

DRUG

Paracetamol

After the block regression, at the first analgetic request the patients received the same analgesia protocol

DRUG

Morphine

After the block regression, at the first analgetic request the patients received the same analgesia protocol

DRUG

Lidocaine

One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Sponsors & Collaborators

  • Foisor Orthopedics Clinical Hospital

    lead OTHER

Principal Investigators

  • Ioan Cristian Stoica, MD Prof · Foisor Orthopedics Clinical Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Romania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698995 on ClinicalTrials.gov